Coronary revascularization in patients with HIV

Trends Cardiovasc Med. 2022 Apr;32(3):163-169. doi: 10.1016/j.tcm.2021.02.006. Epub 2021 Feb 21.

Abstract

With combined antiretroviral therapy, people living with HIV (PLWH) survive longer and are now more likely to die from cardiovascular diseases. PLWH presenting with a ST-segment elevation myocardial infarction are likely to have a high thrombus burden and are at high risk for in-hospital and long-term adverse events. An increasing number of PLWH are presenting with stable coronary artery disease related to atherosclerosis. Revascularization in these patients is associated with higher in-hospital and long-term major adverse cardiovascular events, including stent thrombosis and in-stent restenosis. However, data in this expanding population concerning optimal revascularization strategy are still lacking. In particular, data comparing percutaneous versus surgical revascularization in PLWH are needed. In this review we highlight the currently available data related to coronary revascularization in PLWH.

Keywords: Acute coronary syndromes; Coronary artery disease; HIV; Human immunodeficiency virus; People living with HIV; Revascularization.

Publication types

  • Review

MeSH terms

  • Coronary Artery Bypass
  • Coronary Artery Disease* / diagnostic imaging
  • Coronary Artery Disease* / therapy
  • Coronary Restenosis / therapy
  • HIV Infections* / complications
  • HIV Infections* / diagnosis
  • HIV Infections* / drug therapy
  • Humans
  • Myocardial Infarction*
  • Percutaneous Coronary Intervention*
  • Treatment Outcome